Dukakis stars in Novo Nordisk diabetes awareness PSAs

Share this article:
Dukakis stars in Novo Nordisk diabetes awareness PSAs
Dukakis stars in Novo Nordisk diabetes awareness PSAs
Novo Nordisk recruited actress Olympia Dukakis and her husband, actor Louis Zorich, for a diabetes awareness PSA debuting in New York City taxis next month.

Dukakis, 78, and Zorich, 85, appear in the latest iteration of Novo Nordisk's “Ask. Screen. Know.” campaign, urging people 65 and over to ask their doctor for a free diabetes screening. Zorich was diagnosed with type 2 diabetes during his last screening.

The spot, which will also air on CNN's airport network, encourages viewers to visit AskScreenKnow.com, where they can send emails or voicemails to friends and family from Dukakis urging them to take advantage of a Medicare benefit covering diabetes screenings.

In addition, Dukakis and Zorich will speak at AARP's Vegas@50+ convention October 23, and will be available for interviews in November, which is Diabetes Awareness Month. Banner ads will run on sites targeting seniors, including AARP.org and Eons.com.

Seven out of 10 US adults age 65 and older have diabetes or pre-diabetes, the company said. Fewer than 10% of older adults on Medicare are taking advantage of the free screening benefit.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...